Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
74°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
189.26
-2.14 (-1.12%)
Official Closing Price
Updated: 6:30 PM EDT, Jul 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
10 Health Care Stocks Whale Activity In Today's Session
March 21, 2025
Via
Benzinga
AbbVie Options Trading: A Deep Dive into Market Sentiment
March 20, 2025
Via
Benzinga
Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends
March 20, 2025
Via
The Motley Fool
Elliott Wave Technical Analysis: AbbVie Inc. - Wednesday, March 19
March 19, 2025
A pullback in Wave {iv} is expected before resuming the overall trend.
Via
Talk Markets
Topics
Stocks / Equities
3 Dividend Stocks to Buy for Reliable Passive Income
March 19, 2025
Via
The Motley Fool
AbbVie Options Trading: A Deep Dive into Market Sentiment
March 07, 2025
Via
Benzinga
13 Analysts Have This To Say About AbbVie
March 04, 2025
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
March 04, 2025
Via
Benzinga
AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients
March 17, 2025
AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits and consistent safety data.
Via
Benzinga
1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction
March 16, 2025
Via
The Motley Fool
Topics
ETFs
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025
March 14, 2025
Via
The Motley Fool
Topics
ETFs
Stocks
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
March 14, 2025
Via
The Motley Fool
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
March 12, 2025
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.
Via
Investor's Business Daily
Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.
March 12, 2025
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
March 11, 2025
Via
Benzinga
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
March 11, 2025
Vanguard has some excellent dividend ETFs, but they are right for different investors.
Via
The Motley Fool
Topics
ETFs
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
March 11, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...
Via
StockStory
Topics
Artificial Intelligence
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
March 10, 2025
There's a lot going on for investors.
Via
The Motley Fool
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
March 10, 2025
Via
The Motley Fool
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
March 10, 2025
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...
Via
Stocktwits
3 Stocks Breaking Out Right Now
March 09, 2025
These three stocks are touching new all-time highs.
Via
Talk Markets
Topics
Stocks / Equities
Is the SPDR S&P 500 ETF Trust the Smartest Investment You Can Make Today?
March 09, 2025
Via
The Motley Fool
Topics
ETFs
Stocks
3 Cheap Stocks to Buy With Your Tax Refund Check
March 07, 2025
Via
The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
March 07, 2025
Via
The Motley Fool
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
March 04, 2025
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.
Via
StockStory
Topics
Artificial Intelligence
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
March 03, 2025
AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.
Via
Benzinga
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
March 03, 2025
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.
Via
Investor's Business Daily
These Vanguard ETFs Show Where the Smart Money Is Moving Now
March 03, 2025
Via
The Motley Fool
Topics
ETFs
4 Sectors That Thrive When Inflation Runs Hot
February 28, 2025
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value
Via
MarketBeat
Topics
Economy
World Trade
3 Reasons ABBV is Risky and 1 Stock to Buy Instead
February 28, 2025
AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%.
Via
StockStory
Topics
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.